Literature DB >> 14509414

The effect of legal and hospital policies on physician response to prenatal substance exposure.

David Mendez1, Peter D Jacobson, Kristen M Hassmiller, Gail L Zellman.   

Abstract

OBJECTIVES: To determine the influence of a state's legal environment and a hospital's Prenatal Substance Exposure (PSE) protocol on physicians' propensity to respond when prenatal substance exposure is suspected.
METHODS: Using a sample of 1367 physicians from every state and the District of Columbia, we formulate a set of linear models to determine the impact of the legal environment and hospital protocol on physicians' response to PSE, the agreement between physicians' perceptions and actual state legal environments, and physicians' motivation to act when PSE is suspected.
RESULTS: Both protocol and legal environment showed to be significantly correlated with physicians' propensity to take action when PSE is suspected (p < 0.05). Our analysis shows that physicians prefer a public health (patient-centered) approach to more punitive measures.
CONCLUSIONS: Our results suggest a policy strategy focused first on enacting laws that would encourage a patient-centered approach, by developing and using hospital protocols to implement state policy, and then on educating physicians about the actual legal environment.

Entities:  

Mesh:

Year:  2003        PMID: 14509414     DOI: 10.1023/a:1025188405300

Source DB:  PubMed          Journal:  Matern Child Health J        ISSN: 1092-7875


  8 in total

1.  Physician response to prenatal substance exposure.

Authors:  G L Zellman; R M Bell; C Archie; H DuPlessis; J Hoube; A Miu
Journal:  Matern Child Health J       Date:  1999-03

2.  A search for guidance: examining prenatal substance exposure protocols.

Authors:  Gail L Zellman; Christine Fair; Jill Houbé; Michael Wong
Journal:  Matern Child Health J       Date:  2002-09

3.  National survey of the states: policies and practices regarding drug-using pregnant women.

Authors:  W Chavkin; V Breitbart; D Elman; P H Wise
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

4.  Problems and promises of the protocol.

Authors:  M Berg
Journal:  Soc Sci Med       Date:  1997-04       Impact factor: 4.634

5.  Perspectives of pregnant substance-using women: findings from the California Perinatal Needs Assessment.

Authors:  D Klein; E Zahnd
Journal:  J Psychoactive Drugs       Date:  1997 Jan-Mar

6.  Cocaine use during pregnancy: adverse perinatal outcome.

Authors:  S N MacGregor; L G Keith; I J Chasnoff; M A Rosner; G M Chisum; P Shaw; J P Minogue
Journal:  Am J Obstet Gynecol       Date:  1987-09       Impact factor: 8.661

7.  The relationship between recent cocaine use and pregnancy outcome.

Authors:  M R Spence; R Williams; G J DiGregorio; A Kirby-McDonnell; M Polansky
Journal:  Obstet Gynecol       Date:  1991-09       Impact factor: 7.661

8.  Perinatal screening for illicit drugs: policies in hospitals in a large metropolitan area.

Authors:  M Birchfield; J Scully; A Handler
Journal:  J Perinatol       Date:  1995 May-Jun       Impact factor: 2.521

  8 in total
  4 in total

1.  Physician response to prenatal substance exposure.

Authors:  G L Zellman; R M Bell; C Archie; H DuPlessis; J Hoube; A Miu
Journal:  Matern Child Health J       Date:  1999-03

2.  Reciprocal obligations: managing policy responses to prenatal substance exposure.

Authors:  Peter D Jacobson; Gail L Zellman; C Christine Fair
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

3.  The effect of race on provider decisions to test for illicit drug use in the peripartum setting.

Authors:  Hillary Veda Kunins; Eran Bellin; Cynthia Chazotte; Evelyn Du; Julia Hope Arnsten
Journal:  J Womens Health (Larchmt)       Date:  2007-03       Impact factor: 2.681

4.  Development of the drug-exposed infant identification algorithm (DEIIA) and its application to measuring part C early intervention referral and eligibility in Massachusetts, 1998-2005.

Authors:  Taletha Mae Derrington
Journal:  Matern Child Health J       Date:  2013-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.